Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its financial report for the fourth quarter and full year of 2023. The company’s global revenues for the 12-month period reached EUR 43.07 billion (USD 47 billion), marking a 5.3% increase year-on-year in constant currency terms. Key drivers of this growth included Dupixent (dupilumab) with EUR 10.7 billion (USD 11.68 billion) after a 34% year-on-year increase, the vaccine business’s 8.3% year-on-year growth, Beyfortus (nirsevimab) with EUR 547 million in sales, and the consumer health division’s 6.3% year-on-year growth. In the fourth quarter of 2023, Sanofi recorded revenues of EUR 10.919 billion (USD 11.9 billion), up 9.3% year-on-year.
Pharmaceuticals segment revenues amounted to EUR 37.89 billion (USD 41.3 billion) for the year, up 5.1% year-on-year, driven by specialty medicines and vaccines.
Regionally, the US contributed EUR 18.512 billion, up 4.8%, Europe contributed EUR 10.392 billion, up 4.3%, and other regions contributed EUR 14.166 billion, up 6.5%. China’s revenues were EUR 2.912 billion (USD 3.17 billion), up 0.4% year-on-year.
In the fourth quarter of 2023, Sanofi’s China sales surged 19.2% year-on-year to EUR 644 million (USD 701 million), driven by Dupixent, Toujeo (insulin glargine U300), and Plavix (clopidogrel). China and Japan contributed to Dupixent’s 52.5% year-on-year growth in the fourth quarter. Toujeo’s sales reached EUR 278 million, up 11.4%, with its market share surpassing that of Lantus, driven by China. Plavix generated EUR 254 million, up 13.1% year-on-year, primarily due to China.
Dupixent has been filed for market approval in both China and the US to treat chronic obstructive pulmonary disease (COPD). Beyfortus, an RSV prophylactic antibody co-developed with MSD, was approved for the China market in December 2023.
Paul Hudson, Sanofi’s Chief Executive Officer, commented, “2023 marked a critical year on our journey to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth. We have delivered another year of strong underlying performance of our core drivers in Specialty Care and Vaccines supported by the outstanding launch execution of Beyfortus, Altuviiio, and Tzield. With scientific news flow at an all-time high, pipeline advances, and 12 potential blockbusters in late-stage development including amlitelimab, frexalimab, and tolebrutinib, our R&D transformation has reached an inflection point on the road to industry leadership in immunology. Looking forward, we remain committed to investing in R&D to fully unlock the value of our pipeline, powered by AI at scale, and continue to focus on our expected launch opportunities such as Dupixent in COPD. At the same time, we are taking steps to become a pure-play biopharma company with more than EUR 10 billion sales contribution from Pharma launches by 2030.”- Flcube.com
